Healthcare >> Analyst Interviews >> October 12, 2001
Small & Mid-cap Biotechnology Stocks: Andrew Gitkin – Ubs Warburg
ANDREW A. GITKIN, Executive Director, joined UBS Warburg in November
2000 as a Senior Biotechnology Analyst. Mr. Gitkin's area of coverage
consists of companies in the therapeutic categories of cancer and
central nervous system disorders. Prior to his employment at UBS
Warburg, Mr. Gitkin was a Senior Vice President at PaineWebber, where he
worked since March 1999. At PaineWebber, Mr. Gitkin was a Senior
Healthcare Analyst. Prior to his employment at PaineWebber, Mr. Gitkin
was a Vice President at Salomon Smith Barney, where he worked since July
1994. There, his coverage responsibilities included medical
technology/devices and healthcare services. In total, Mr. Gitkin
possesses more than six years of experience following various components
of the healthcare sector. During the past three years, Mr. Gitkin was
one of the top three rated long-term care analysts according to the
Greenwich Associates poll of research analysts. Most recently, Mr.
Gitkin was ranked as one of the top 10 healthcare analysts according to
Institutional Investor magazine. Furthermore, in 1998, Mr. Gitkin was
named as one of the top 40 professionals in New York according to
Crain's magazine's Forty Under Forty Poll. Mr. Gitkin received his BBA
from Emory University, where he graduated with distinction. Profile
TWST: What do you include in your coverage area?
Mr. Gitkin: I focus on small and mid-cap biotech companies, from the
$200 million market capitalization up to around $3.5-$4 billion.